Amgen (AMGN) Posts Phase 3 Lung Cancer Data With 58% Lower Death Risk

Simply Wall St.13:29

Amgen (NasdaqGS:AMGN) reported interim Phase 3 data for IMDELLTRA plus IMFINZI in first line extensive stage small cell lung cancer. The IMDELLTRA and IMFINZI combination reduced the risk of death and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2678592181?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684","is_english":true,"pubTime":"2026-10-26 13:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2678592181","market":"sg","top_or_hot":-1,"title":"Amgen (AMGN) Posts Phase 3 Lung Cancer Data With 58% Lower Death Risk","media":"Simply Wall St.","content":"<div>\n<p>Amgen (NasdaqGS:AMGN) reported interim Phase 3 data for IMDELLTRA plus IMFINZI in first line extensive stage small cell lung cancer. The IMDELLTRA and IMFINZI combination reduced the risk of death and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-posts-phase-3-lung-cancer-data-with-58-lower-deat\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen (AMGN) Posts Phase 3 Lung Cancer Data With 58% Lower Death Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen (AMGN) Posts Phase 3 Lung Cancer Data With 58% Lower Death Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-26 13:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-posts-phase-3-lung-cancer-data-with-58-lower-deat><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amgen (NasdaqGS:AMGN) reported interim Phase 3 data for IMDELLTRA plus IMFINZI in first line extensive stage small cell lung cancer. The IMDELLTRA and IMFINZI combination reduced the risk of death and...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-posts-phase-3-lung-cancer-data-with-58-lower-deat\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-posts-phase-3-lung-cancer-data-with-58-lower-deat","article_id":"2678592181","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/24816-card/1789038959684"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/amgen-amgn-posts-phase-3-lung-cancer-data-with-58-lower-deat","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2678592181","pubTimestamp":1792992573,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Amgen (NasdaqGS:AMGN) reported interim Phase 3 data for IMDELLTRA plus IMFINZI in first line extensive stage small cell lung cancer.\nThe IMDELLTRA and IMFINZI combination reduced the risk of death and disease progression compared with current standard therapy in the study.\nInvestigators reported longer median overall survival and progression free survival for patients receiving the dual immunotherapy regimen.\nThere is more to Amgen than the IMDELLTRA and IMFINZI lung cancer data, including...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","BK4566":"资本集团","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BBH":"VanEck Biotech ETF","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","PJP":"INVESCO PHARMACEUTICALS ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","AMGN":"安进","BIB":"Ultra纳斯达克生物科","IBB":"生物科技指数ETF-iShares Nasdaq","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0058720904.USD":"联博国际健康护理基金A","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4581":"高盛持仓","BK4599":"减肥药","LU1236620750.USD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","BK4534":"瑞士信贷持仓","BK4139":"生物科技"},"translate_title":"安进 (AMGN) 发布 3 期肺癌数据，死亡风险降低 58%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PJP":0.6,"IBBQ":0.6,"AMGN":1.5,"BBH":0.6,"PBE":0.6,"TBXU":0.6,"IBB":0.6,"BIB":0.6},"content_text":"Amgen (NasdaqGS:AMGN) reported interim Phase 3 data for IMDELLTRA plus IMFINZI in first line extensive stage small cell lung cancer. The IMDELLTRA and IMFINZI combination reduced the risk of death and disease progression compared with current standard therapy in the study. Investigators reported longer median overall survival and progression free survival for patients receiving the dual immunotherapy regimen. There is more to Amgen than the IMDELLTRA and IMFINZI lung cancer data, including risks that investors should understand. We have also spotted 1 warning sign worth knowing about at Amgen.  For readers interested in more ideas linked to this kind of medical and data heavy work, the next stop is 55 AI infrastructure stocks. NasdaqGS:AMGN Earnings & Revenue Growth as at Oct 2026 Amgen is a large US biotech group with a reported market value of about $237.5b that focuses on discovering and producing human therapeutics, so investors often look at late stage trial readouts like this as signals about how its research pipeline might translate into future treatment options. 4 things going right for Amgen that this headline doesn't cover. AdvertisementWhat IMDELLTRA means for Amgen’s oncology upside and its bear-case stress test For Amgen, these IMDELLTRA and IMFINZI data lean into one of the core bullish arguments in the Narrative, which is that newer oncology biologics can help support a broad earnings base as older drugs face pricing pressure and biosimilar competition. A 58% reduction in risk of death and 66% reduction in risk of progression or death in first line extensive stage small cell lung cancer speaks to market opportunity in a tough indication where treatment options have been limited, and it gives more weight to the idea that Amgen’s oncology franchise can be a meaningful pillar alongside cardiometabolic and rare disease assets. See how these catalysts shape Amgen's path to a $391 fair value. Investors now have a clear near term checkpoint. The key marker is how quickly Amgen can translate these Phase 3 results into regulatory filings and, if approved, real world uptake, with attention on any guidance the company gives at upcoming conferences or earnings calls about IMDELLTRA’s initial contribution within the oncology portfolio and how it fits into the mix of the six key growth drivers that already account for nearly 70% of product sales. One more thing about Amgen that investors cannot see in a trial readout Clinical headlines only tell part of the story for Amgen. A separate, cash-flow-based estimate of what this enterprise could reasonably be worth exists, and it can be lined up against where the share price trades today. Find out exactly what Amgen is worth today based on its cash flows. This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2678592181","isCrawlerRequest":true}